Assignee
BEAM THERAPEUTICS INC
US·14 granted patents·71 pending applications·37 citations·filing 2019–2025
Top patents by PatentIndex Score
85 records- 0196US11344609B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2021·Granted May 31, 2022·6 cites·34 claims
- 0296US11142760B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2021·Granted Oct 12, 2021·14 cites·30 claims
- 0395US11752202B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·3 cites·28 claims
- 0493US2026061041A1Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0592US11155803B2Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2020·Granted Oct 26, 2021·13 cites·30 claims
- 0681US12016908B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2022·Granted Jun 25, 2024·0 cites·14 claims
- 0779US2025025573A1Novel rna base editing compositions, systems, methods and uses thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0878US12133884B2Methods of substituting pathogenic amino acids using programmable base editor systemsBEAM THERAPEUTICS INC·Filed 2019·Granted Nov 5, 2024·1 cites·4 claims
- 0976US2025108098A1Methods of substituting pathogenic amino acids using programmable base editor systemsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1076US2024132867A1Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1175US12296053B2Nanomaterials comprising triolsBEAM THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·0 cites·26 claims
- 1273US2025144149A1Adenosine deaminase base editors and methods for use thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1370US2022235347A1Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1469US2024327813A1Crispr enzymes, methods, systems and uses thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1569US2024158775A1Adenosine deaminase variants and uses thereofBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1668US2025041441A1NanomaterialsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1768US2024327802A1Chimeric pseudotyped recombinant rabies virusBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1867US2025108132A1Compositions and methods for reducing complement activationBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1967US2024252550A1Genetic modification of hepatocytesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2066US2025090585A1Modified regulatory t cells and methods of using the sameBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2166US2025288690A1Rna base editing compositions, systems, methods and uses thereofBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2265US2023270840A1Viral guide rna deliveryBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2364US2024325533A1Modified immune cells and methods of using the sameBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2464US2024124536A1Base editing of transthyretin geneBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2563US2024376468A1CIRCULAR GUIDE RNAs FOR CRISPR/CAS EDITING SYSTEMSBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2662US2024132868A1Compositions and methods for the self-inactivation of base editorsBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2762US2024117345A1Compositions and methods for treating transthyretin amyloidosisBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2862US2022290164A1Recombinant rabies viruses for gene therapyBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2962US2024335516A1Compositions and methods for the treatment of spinal muscular atrophy (sma)BEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3061US12268753B2Nanomaterials comprising a biodegradable featureBEAM THERAPEUTICS INC·Filed 2022·Granted Apr 8, 2025·0 cites·14 claims
- 3161US2024358841A1Nanomaterials comprising tetravalent lipid compoundsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3261US2025102524A1Hemoglobin g-makassar binding polypeptides and antibodies and methods of using the sameBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3361US2024335542A1Nanomaterials comprising disulfidesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3461US2024335543A1Ionizable amine and ester lipids and lipid nanoparticlesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3560US12059477B2NanomaterialsBEAM THERAPEUTICS INC·Filed 2022·Granted Aug 13, 2024·0 cites·27 claims
- 3660US2024335541A1Nanomaterials comprising diaminesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3760US2024167008A1Novel crispr enzymes, methods, systems and uses thereofBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3860US2024335385A1Ionizable amine lipids and lipid nanoparticlesBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3960US2025092450A1Identification of nanoparticles for preferential tissue or cell targetingBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4059US2024287453A1Persistent allogeneic modified immune cells and methods of use thereofBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4159US2024301405A1Guide rnas for crispr/cas editing systemsBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4259US2024294914A1Compositions and methods for treating hepatitis b virus infectionBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4359US2024360433A1Compositions and methods for the treatment of hereditary angioedema (hae)BEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4459US2025213493A1Nanomaterials comprising triolsBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4558US2026062704A1Compositions and methods for treating stargardt diseaseBEAM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4657US2023110201A1Pseudotyped recombinant lyssaviruses for gene therapyBEAM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4756US2023331657A1Nanomaterials comprising ester-linked acetalsBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4855US2023357133A1Nanomaterials comprising carbonatesBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4955US2022170027A1Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5055US2023242884A1Compositions and methods for engraftment of base edited cellsBEAM THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BEAM THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →